In Good Company

In the era of precision medicine and companion diagnostics, it's not enough to just get a drug approved anymore.

Learn more

Conflict of Conscience

In Editor's Corner, Mikkael Sekeres discloses some of the unconventional conflicts of interest clinicians may have.

Learn more

ASH Meeting on Lymphoma Biology

Reports from the ASH Meeting on Lymphoma Biology, including R-EPOCH for DLBCL and ibrutinib in high-risk CLL/SLL.

Learn more

Written in Blood

Brentuximab vedotin leads to long-term remissions in patients with relapsed/refractory Hodgkin lymphoma.

Learn more

On Location

Reports from the European Hematology Association's 21st Annual Congress

Learn more
Advertisement

New Exclusive Videos

View all Exclusive Videos

  • Conflict of Conscience

    On the first Wednesday of every month, the Innovation Management and Conflict of Interest Committee at Cleveland Clinic meets to discuss some of the thornier issues that have arisen with our staff members and their relationships with external entities. I am a standing member of this committee, and the majority of our discussions center on […]

  • Magical Thinking

    Okay, I confess. I exhibit magical thinking. I believe in jinxes, in woo woo, and in all of the medical lore and superstitions I learned as a resident. My superstitions are limited to the realm of medicine, though. I don’t care when Friday the 13th rolls around, or when black cats cross my path, or […]

  • Recommendations from My Bookshelf: Cutting for Stone by Abraham Verghese

    Have you ever been a stranger in a strange land? I thought I was when I moved from New England to Cleveland, where I had to learn to talk a little slower, and that unfamiliar people who smiled and said “hi” as they passed me in the hallways were not mentally unstable – as I […]

  • Kindred Spirits

    “Kindred spirits are not so scarce as I used to think. It’s splendid to find out there are so many of them in the world.” ― L.M. Montgomery, Anne of Green Gables Despite the cultural and political differences that divide us, humans across the globe are remarkably similar. As Sting once sang, “We share the […]

View all Editor`s Corner
  • FLT3 Inhibitors in Older Patients with Acute Myeloid Leukemia: More Questions Than Answers?

    Acute myeloid leukemia (AML) affects primarily older adults (with a median age of 67 years at diagnosis), and management of the disease in this population represents a therapeutic challenge – given their comorbidities and susceptibility to treatment-related toxicities. Patients who also harbor the FLT3 mutation face a particularly poor prognosis, with a high chance of […]

  • Optimal Timing of Transplant in Myeloma

    New therapeutic options for the treatment of multiple myeloma are capable of achieving sustained and deep remissions, calling into question the role of upfront stem cell transplantation. ASH Clinical News has invited Shaji Kumar, MD, and Ola Landgren, MD, to debate the question: “What is the optimal timing for hematopoietic cell transplantation in patients with […]

  • Should IVC Filters Still Be Inserted into Thrombosis Management Guidelines?

    Although the use of inferior vena cava (IVC) filters to prevent thrombosis has increased dramatically in the past decade, the risk-benefit ratio of these devices is unclear. The potential complications associated with filter placement and retrieval may outweigh the benefit, particularly in the era of novel oral anticoagulants. ASH Clinical News invited Joseph M. Stavas, […]

  • For Anticoagulation in Cancer-Associated Thrombosis, Is Less More?

    Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer. While low-molecular-weight heparin (LMWH) anticoagulation therapy is a standard regimen for treating acute thrombotic events in these patients, questions remain about its optimal use, including the duration of anticoagulation. ASH Clinical News invited David A. Garcia, MD, and Agnes Y. Lee, […]

View all Drawing First Blood
  • CMS Tests New Medicare Part B Reimbursement Model: How Will It Affect Hematologists?

    In March, the Centers for Medicare & Medicaid Services (CMS) announced a proposed rule to test new models to improve Medicare Part B physician reimbursements for prescription drugs.1 According to CMS, the rule will test different physician incentives that would, in theory, encourage the prescription of the most effective drugs and reward positive patient outcomes. […]

  • Choosing Wisely Across the Internal Medicine Spectrum: Which Recommendations Should Hematologists Pay Attention To?

    In collaboration with the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign, ASH released a list of hematology-related tests and procedures to question based on recommendations from other medical societies at the 2015 annual meeting. Choosing Wisely encourages clinicians and patients to engage in conversations to reduce waste and overuse in health care. […]

  • New Medicare Care Choices Model Seeks to Expand Access to Palliative Care

    On July 20, 2015, the Centers for Medicare& Medicaid Services (CMS) announcedthe 141 hospices that have been selected to participate in the new Medicare Care Choices Model (MCCM), a pilot program designed to expand patients’ access to palliative and hospice care.1 The new model provides clinicians, beneficiaries, and their families with greater flexibility in deciding between hospice care and active […]

  • ICD-10: Ready or Not!

    After two one-year reprieves, it’s finally here: The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). Nationwide, on October 1, 2015, all health-care business transactions in the United States converted to ICD-10 from the previous version of the ICD (ICD-9). If they did not convert, claims and electronic transactions will be rejected. The ICD-9 […]

View all Practice Update